FGD3
|
0.0044
|
FYVE, RhoGEF and PH domain containing 3 (FGD3), transcript variant X2, misc_RNA
|
4.16E-13
|
−2.02
|
CDH5
|
0.0141
|
cadherin 5, type 2 (vascular endothelium; CDH5), mRNA
|
0.00000179
|
−1.49
|
CASP1
|
0.0096
|
caspase 1, apoptosis-related cysteine peptidase (CASP1), RefSeqGene on chromosome 11
|
0.003233781
|
−0.85
|
C3
|
0.0033
|
complement component 3 (C3), mRNA
|
0.004117402
|
−0.57
|
RDH10
|
0.0204
|
retinol dehydrogenase 10 (all-trans; RDH10), mRNA
|
0.009398676
|
−0.70
|
NEO1
|
0.041
|
neogenin 1 (NEO1), RefSeqGene on chromosome 15
|
0.00995951
|
−0.55
|
CDH11
|
0.0139
|
cadherin 11, type 2, OB-cadherin (osteoblast; CDH11), RefSeqGene on chromosome 16
|
0.01161935
|
−0.52
|
PCTP
|
0.0151
|
phosphatidylcholine transfer protein (PCTP), transcript variant X4, misc_RNA
|
0.014216733
|
−1.20
|
SP110
|
0.0143
|
SP110 nuclear body protein (SP110), RefSeqGene (LRG_109) on chromosome 2
|
0.015998943
|
−0.50
|
NIPSNAP1
|
0.0173
|
nipsnap homolog 1 (C. elegans; NIPSNAP1), transcript variant X1, mRNA
|
0.016613623
|
−0.47
|
BCAS1
|
0.0022
|
breast carcinoma amplified sequence 1 (BCAS1), transcript variant X9, mRNA
|
0.025350687
|
−4.06
|
GABRP
|
0.0273
|
gamma-aminobutyric acid (GABA) A receptor, pi (GABRP), transcript variant 2, mRNA
|
0.031249095
|
−2.79
|
SYCE1L
|
0.0262
|
synaptonemal complex central element protein 1-like (SYCE1L), mRNA
|
0.032750969
|
−0.98
|
PROM1
|
0.0258
|
prominin 1 (PROM1), RefSeqGene on chromosome 4
|
0.038456406
|
−0.54
|
BRAF
|
0.029
|
B-Raf proto-oncogene, serine/threonine kinase (BRAF), RefSeqGene (LRG_299) on chromosome 7
|
0.042463081
|
−0.53
|
SIAE
|
0.0287
|
sialic acid acetylesterase (SIAE), RefSeqGene on chromosome 11
|
0.047026974
|
−0.54
|
VIPR1
|
0.0068
|
vasoactive intestinal peptide receptor 1 (VIPR1), RefSeqGene on chromosome 3
|
0.047041988
|
−0.49
|
| BAZ2B |
0.0057 |
bromodomain adjacent to zinc finger domain, 2B (BAZ2B), transcript variant 3, non-coding RNA |
0.047636931 |
−0.73 |
